As of June 30, 2024, CANSINO BIOLOGICS INC carries a market capitalization of 1.91B, placing it among publicly traded companies globally. Its enterprise value stands at 1.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.91B |
| Enterprise Value | 1.73B |
CANSINO BIOLOGICS INC's next confirmed earnings release is scheduled for March 30, 2027.
| Earnings Date | 3/30/2027 |
As of June 30, 2024, CANSINO BIOLOGICS INC has 833.07M shares outstanding.
| Shares Outstanding | 833.07M |
These figures are as of June 30, 2024. The price-to-sales ratio is 10.77, and the price-to-book ratio stands at 2.75.
| PS Ratio | 10.77 |
| PB Ratio | 2.75 |
| P/TBV Ratio | 2.83 |
These figures are as of June 30, 2024. The EV/Sales ratio of 20.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.73B versus a market cap of 1.91B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 20.65 |
As of June 30, 2024, CANSINO BIOLOGICS INC maintains a current ratio of 2.38, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 43.43, indicating elevated leverage, while an interest coverage ratio of -14.37 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.38 |
| Quick Ratio | 1.85 |
| Debt / Equity | 43.43 |
| Debt / EBITDA | -2.26 |
| Interest Coverage | -14.37 |
Over the twelve months ended June 30, 2024, CANSINO BIOLOGICS INC posted a negative return on equity (ROE) of -15.80, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.61, reflecting losses generated across the asset base. The company generates approximately 49,536.67 in revenue per employee across its workforce of 1,693.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.28 indicates how many times CANSINO BIOLOGICS INC sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -15.80 |
| Return on Assets (ROA) | -9.61 |
| Revenue Per Employee | 49,536.67 |
| Employee Count | 1,693.25 |
| Inventory Turnover | 1.28 |
Over the twelve months ended June 30, 2024, CANSINO BIOLOGICS INC recorded an income tax benefit of -1.28M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -127.26M and -119.27M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -1.28M |
As of the close on November 13, 2026, CANSINO BIOLOGICS INC's stock has declined approximately 44.64% over the past 52 weeks. The 50-day moving average sits at 4.41, while the 200-day moving average is 5.34.
| 52-Week Price Change | -44.64% |
| 50-Day Moving Average | 4.41 |
| 200-Day Moving Average | 5.34 |
Over the twelve months ended June 30, 2024, CANSINO BIOLOGICS INC generated 83.88M in revenue and converted that into -119.27M in net income, yielding earnings per share of -0.32. EBITDA reached -133.67M, while operating income came in at -126.68M.
| Revenue | 83.88M |
| Gross Profit | 12.06M |
| Operating Income | -126.68M |
| Pretax Income | -127.26M |
| Net Income | -119.27M |
| EBITDA | -133.67M |
| EBIT | -133.67M |
| Earnings Per Share (EPS) | -0.32 |
As of June 30, 2024, CANSINO BIOLOGICS INC holds 485.58M in cash and equivalents against 302.36M in total debt, resulting in a net debt position of 62.43M. Total book value stands at 696.26M, with working capital of 362.05M providing operational flexibility.
| Cash & Cash Equivalents | 485.58M |
| Total Debt | 302.36M |
| Net Debt | 62.43M |
| Equity (Book Value) | 696.26M |
| Book Value Per Share | 0.84 |
| Working Capital | 362.05M |
These figures cover the twelve months ended June 30, 2024.
| Capital Expenditures | -66.48M |
Over the twelve months ended June 30, 2024, CANSINO BIOLOGICS INC posted a gross margin of 14.38, reflecting its pricing power and cost economics. The operating margin of -151.03 and net profit margin of -142.19 provide insight into operational efficiency.
| Gross Margin | 14.38 |
| Operating Margin | -151.03 |
| Pretax Margin | -151.72 |
| Profit Margin | -142.19 |
| EBITDA Margin | -159.36 |
Over the twelve months ended June 30, 2024, CANSINO BIOLOGICS INC paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.73, meaning CANSINO BIOLOGICS INC raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -0.73 |
As of June 30, 2024, CANSINO BIOLOGICS INC has an Altman Z-Score of 2.49, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.49 |
Already premium?